Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma

Khadra Galaal; Esther van der Heijden; Keith Godfrey; Raj Naik; Ali Kucukmetin; Andrew Bryant; Nagindra Das; Alberto D Lopes

doi:10.1002/14651858.CD006812.pub3

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Respuestas clínicas Cochrane
Guías
Temas

Revisiones y protocolos relacionados

Respuestas clínicas Cochrane

Topics

Temas

Figure 1

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 2

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.1

Comparison 1 Combination therapy versus Ifosfamide, Outcome 1 Overall survival.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 Combination therapy versus Ifosfamide, Outcome 2 Progression‐free survival.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 Combination therapy versus Ifosfamide, Outcome 3 G3‐4 Nausea/vomiting.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 Combination therapy versus Ifosfamide, Outcome 4 Diarrhoea and other GI.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.5

Comparison 1 Combination therapy versus Ifosfamide, Outcome 5 Haematological.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.6

Comparison 1 Combination therapy versus Ifosfamide, Outcome 6 Genitourinary.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.7

Comparison 1 Combination therapy versus Ifosfamide, Outcome 7 Cardiovascular.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.8

Comparison 1 Combination therapy versus Ifosfamide, Outcome 8 Hepatic.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.9

Comparison 1 Combination therapy versus Ifosfamide, Outcome 9 Neuropathy.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.1

Comparison 2 Whole body irradiation versus chemotherapy, Outcome 1 Overall survival.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.2

Comparison 2 Whole body irradiation versus chemotherapy, Outcome 2 Progression‐free survival.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.3

Comparison 2 Whole body irradiation versus chemotherapy, Outcome 3 G3‐4 Gastrointestinal.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.4

Comparison 2 Whole body irradiation versus chemotherapy, Outcome 4 Haematological.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.5

Comparison 2 Whole body irradiation versus chemotherapy, Outcome 5 Genitourinary.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.6

Comparison 2 Whole body irradiation versus chemotherapy, Outcome 6 Cardiovascular.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.7

Comparison 2 Whole body irradiation versus chemotherapy, Outcome 7 Hepatic.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.8

Comparison 2 Whole body irradiation versus chemotherapy, Outcome 8 Neuropathy.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1. Combination therapy versus Ifosfamide

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival Show forest plot	2	373	Hazard Ratio (Random, 95% CI)	0.75 [0.60, 0.94]

2 Progression‐free survival Show forest plot	2	373	Hazard Ratio (Random, 95% CI)	0.72 [0.58, 0.90]

3 G3‐4 Nausea/vomiting Show forest plot	2	365	Risk Ratio (IV, Random, 95% CI)	3.53 [1.33, 9.37]

4 Diarrhoea and other GI Show forest plot	2	365	Risk Ratio (IV, Random, 95% CI)	1.51 [0.31, 7.52]

5 Haematological Show forest plot	2	365	Risk Ratio (IV, Random, 95% CI)	1.56 [0.84, 2.90]

6 Genitourinary Show forest plot	2	365	Risk Ratio (IV, Random, 95% CI)	1.68 [0.54, 5.18]

7 Cardiovascular Show forest plot	2	365	Risk Ratio (IV, Random, 95% CI)	0.63 [0.13, 3.11]

8 Hepatic Show forest plot	1	174	Risk Ratio (IV, Random, 95% CI)	2.05 [0.73, 5.74]

9 Neuropathy Show forest plot	2	365	Risk Ratio (IV, Random, 95% CI)	1.59 [0.99, 2.55]

Comparison 1. Combination therapy versus Ifosfamide

Ir a la tabla de la revisión

Comparison 2. Whole body irradiation versus chemotherapy

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival Show forest plot	1		Hazard Ratio (Random, 95% CI)	Subtotals only

2 Progression‐free survival Show forest plot	1		Hazard Ratio (Random, 95% CI)	Subtotals only

3 G3‐4 Gastrointestinal Show forest plot	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only

4 Haematological Show forest plot	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only

5 Genitourinary Show forest plot	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only

6 Cardiovascular Show forest plot	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only

7 Hepatic Show forest plot	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only

8 Neuropathy Show forest plot	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only

Comparison 2. Whole body irradiation versus chemotherapy

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet